Infectious Disease Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The infectious disease drugs market size was valued at USD 189.80 billion in 2025 and is estimated to grow from USD 195.83 billion in 2026 to reach USD 228.95 billion by 2031, at a CAGR of 3.18% during the forecast period (2026-2031). This report is Segmented by Disease (HIV, Influenza, Hepatitis and More), Treatment Class (Antiviral, Antibacterial, Antiparasitic, and More), Drug Type (Small-Molecule, Biologic/MAb and More), Route of Administration (Oral, Injectable and More), Distribution Channel (Hospital Pharmacies, Retail & Chain Pharmacies and More) Geography. The Market Forecasts are Provided in Terms of Value (USD).

Global Infectious Disease Drugs Market Trends and Insights

Growing Prevalence of Infectious Diseases

Drug-resistant pathogens claim around 700,000 lives every year, underscoring a structural demand for better medicines. Tuberculosis now affects 10.8 million people, with resistant strains spreading quickly.Artemisinin-resistant malaria has been confirmed in Rwanda and Tanzania, jeopardizing earlier public-health gains. Surveillance in Uganda shows 11% of children harbor partial resistance to front-line malaria therapy. Aging populations, cancer-related immunosuppression, and climate-shifted vector habitats layer further demand on the infectious disease drugs market. Collectively, these epidemiological pressures sustain mid-single-digit growth for specialized therapies despite stewardship curbs.

AI-Driven Antimicrobial Discovery Platforms

Machine-learning engines now sift chemical libraries in weeks, not years. Eli Lilly’s USD 100 million pact with OpenAI illustrates pharma’s largest single AI commitment to tackle resistance. CRISPR-optimized phage LBP-EC01 is entering Phase 2 trials with USD 23.9 million in BARDA funding. SNIPR Biome dosed the first volunteers with a genome-edited antibiotic that spares commensal flora. Predictive algorithms flag resistance pathways early, guiding chemists toward compounds less likely to fail in vivo. As platform proof points accumulate, capital flows tilt toward AI-native pipeline builders, reshaping the infectious disease drugs market’s innovation map.

Antimicrobial Stewardship Curbing Prescriptions

Hospitals now require pre-authorization for broad-spectrum antibiotics, cutting usage by up to 30% in some systems. Remote telehealth visits, however, escape many controls, prompting fresh audit tools. The European Union blueprint is spreading worldwide, formalizing daily-dose caps and treatment-length ceilings. While stewardship slows units sold, it is catalyzing demand for narrow-spectrum therapies positioned as resistance-sparing, thus reshaping revenue composition inside the infectious disease drugs market.

Other drivers and restraints analyzed in the detailed report include:

• Expanding Funding & R&D Investments
• Accelerated Regulatory Pathways Post-COVID-19
• API Supply-Chain Fragility & Geopolitics

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

HIV therapies held 36.10% of 2025 revenue, giving the infectious disease drugs market a core cash generator that funds riskier pipeline bets. Long-acting cabotegravir-rilpivirine autoinjectors, administered every two months, improved real-world viral suppression rates, lifting lifetime adherence and revenue consistency. In contrast, hepatitis treatments are projected to grow at a 3.98% CAGR, courtesy of bulevirtide’s 90% sustained virologic response in hepatitis D trials.Eliminating chronic hepatitis outcomes is a priority for payers aiming to curb organ-transplant costs. Tuberculosis therapies ride policy urgency as PurF inhibitor JNJ-6640 posts potent activity against multidrug-resistant strains. Malaria portfolios focus on triple combination regimens to offset artemisinin resistance documented in East Africa. Influenza antivirals gain from surveillance systems built during COVID-19, while opportunistic infection drugs rise with cancer-therapy-driven immunosuppression.

The hepatitis surge widens therapy choice, attracting regional generic entrants faster than in HIV, yet intellectual-property cliffs in 2028 could reshape pricing. Meanwhile, pipeline assets for tuberculosis and malaria often rely on nonprofit co-funding, implying slower commercialization but high public-health value. For HIV, the challenge is next-generation broadly neutralizing antibodies that aim to cut dosing to twice yearly, a shift with potential to defend market incumbency. Collectively, disease-specific dynamics keep the infectious disease drugs market balanced between cash-rich chronic segments and fast-rising acute segments.

Antivirals generated 40.80% of 2025 revenue, reflecting entrenched HIV and hepatitis franchises. Yet novel phage and CRISPR-enabled treatments are on track for a 5.41% CAGR, racing to clinical proof via adaptive trials that measure rapid microbiological outcomes. Locus Biosciences’ LBP-EC01 achieved significant bacterial load reduction in urinary tract infections within 24 hours. Antibacterials find fresh life through long-acting glycopeptides that permit outpatient dosing, appealing to payers eager to cut hospital stays. Antifungals like fosmanogepix address the surge in Aspergillus resistance among transplant recipients. Antiparasitics counter emergent mutations with triple-drug blends now in Phase 3.

The infectious disease drugs market size for novel classes remains small today, yet pipeline density suggests rapid upside as regulators validate surrogate endpoints. Success will depend on companion diagnostics that confirm pathogen identity, ensuring narrow-spectrum agents reach the right patients and qualify for value-based contracts. In short, the competitive field is widening beyond chemical antivirals to include precision biological modalities.

Complete Report Scope:

• By Disease
  • HIV
  • Influenza
  • Hepatitis (A, B, C, D & E)
  • Tuberculosis
  • Malaria
  • Opportunistic & other infections
• By Treatment Class
  • Antiviral
  • Antibacterial
  • Antiparasitic
  • Antifungal
  • Novel phage & CRISPR-based therapeutics
• By Drug Type
  • Small-molecule
  • Biologic / mAb
  • Vaccine-derived therapeutics
• By Route of Administration
  • Oral
  • Injectable (IV, IM, SC)
  • Transdermal & Inhalational
• By Distribution Channel
  • Hospital Pharmacies
  • Retail & Chain Pharmacies
  • Online Pharmacies
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America retained 36.20% of 2025 sales, powered by BARDA grants that expedite late-stage trials and by insurers willing to reimburse novel mechanisms that reduce hospitalization. Accelerated FDA pathways encourage early launch, while Canada’s priority review vouchers extend the model region-wide. The United States remains exposed to API import risks, pushing federal proposals for tax credits on domestic fermentation plants. Mexico’s inclusion in continental supply chains offers near-shoring relief but still lacks large-scale sterile capacity.

Asia-Pacific is forecast to grow at a 7.28% CAGR, lifted by regulatory modernization and rising middle-class healthcare spend. China’s NMPA is clearing anti-infective NDAs faster than any peer agency, showing policy urgency on resistance. Singapore bankrolls bacteriophage hubs, while South Korea’s digital health ecosystem supports online antibiotic dispensing. India straddles its role as both API exporter and large therapy consumer, making quality assurance a strategic imperative. Japan, faced with the world’s oldest population median, funds infection prophylaxis in elder-care settings, adding steady volume to the infectious disease drugs market.

Europe balances stewardship-driven volume limits with high adoption of premium therapies that prove outcome gains. Germany and the United Kingdom bankroll basic AMR science, exemplified by the Fleming Initiative. EMA and HERA coordinate stockpiles to blunt shortage risk, a response to recent cephalosporin gaps. Eastern European states modernize procurement rules to attract biosimilar antivirals, boosting regional competitive intensity. The continent’s unified regulatory stance simplifies launch sequences, allowing companies to stage pan-EU rollouts that lift the infectious disease drugs market size more efficiently than piecemeal national filings.

List of Companies Covered in this Report:

• Abbvie
• Boehringer Ingelheim
• Gilead Sciences
• GlaxoSmithKline
• Johnson & Johnson
• Merck
• Novartis
• Roche
• Sanofi
• Takeda Pharmaceuticals
• AstraZeneca
• Pfizer
• Cipla
• Viatris
• Dr. Reddy’s Laboratories Ltd.
• Hikma Pharmaceuticals
• Sun Pharma Industries Ltd.
• Lupin
• Hookipa Pharma
• Bajaj Healthcare Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support